• Home | Global Data CRO
  • Our Company
    • About Us
    • Executive Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Global Leaders
    • Working with MMS
    • Certifications
  • Services
    • Regulatory Affairs
      • Regulatory Affairs Services
      • Regulatory Strategy Consulting
      • Regulatory Affairs Management
      • Regulatory Operations
    • Data Management and Biostatistics
    • Regulatory and Medical Writing
    • Transparency Services
      • Transparency and Disclosure Services
      • REGISTRATION AND RESULTS DISCLOSURES
      • Data and Document Anonymization
      • LAY SUMMARIES
    • Quality and Compliance services
    • Drug Safety and Pharmacovigilance
    • Rare Disease
    • Quality Control Services
    • Project Advisory Services
    • Data Science
  • Technology
    • Datacise
    • Automatiqc
    • PVantage
    • Technology Implementation
    • SmartStart Document Templates
  • Functional Services (FSP)
  • Webinars
  • News and Media
  • MMS Blog
  • Careers
    • MMS Careers
    • Opportunities
    • MMS Experience
    • MMS Culture
    • Global Benefits
    • FAQ
  • Learning
  • Contact Us
MMS Holdings
MMS Holdings To Debut Datacise Integrated Safety Explorer To Detect Safety Signals

MMS Holdings To Debut Datacise Integrated Safety Explorer To Detect Safety Signals

by Avery Zimmerman | Mar 4, 2020 | News

MMS Holdings to Debut Datacise Integrated Safety Explorer to Detect Safety Signals Using Real-World Evidence During PHUSE/FDA Data Science Innovation Challenge CANTON, Mich. (March 4, 2020) – MMS Holdings (MMS) – an award-winning, data-focused CRO – announced today...
The New Roaring 20s: 12 Experts Provide Pharmaceutical Insights for the Decade Ahead

The New Roaring 20s: 12 Experts Provide Pharmaceutical Insights for the Decade Ahead

by Avery Zimmerman | Feb 7, 2020 | Blog

The pharmaceutical industry—and healthcare in general—are in constant stages of innovation. According to the International Federation of Pharmaceutical Manufacturers & Associations, the number of new chemical or biological entities launched on the world market...
Webinar: The Programmers Approach to Real World Data and Using Real World Evidence in Research and Healthcare

Webinar: The Programmers Approach to Real World Data and Using Real World Evidence in Research and Healthcare

by Avery Zimmerman | Oct 3, 2019 | Blog

by MMS Holdings and MichBio.org This webinar is intended to help guide individuals towards a better understanding of core concepts and requirements for using real-world data (RWD). Here, we will delve into how one can derive and utilize real-world evidence (RWE) in...
Using Real World Data in Drug Development: Five Questions with Vijay Ivaturi, PhD

Using Real World Data in Drug Development: Five Questions with Vijay Ivaturi, PhD

by Avery Zimmerman | Aug 22, 2019 | Blog

  The idea and practice of using real world data in the pharmaceutical industry has driven much conversation as of late. As groups like the Health Analytics Collective begin to bring game-changing methodologies to the marketplace, we sat down with Vijay Ivaturi,...
Partner Spotlight: A Conversation with Julia Computing

Partner Spotlight: A Conversation with Julia Computing

by Avery Zimmerman | Jul 11, 2019 | Blog

As an integral member of the Health Analytics Collective, Julia Computing is seen as the programming language of the future. We sat down with Andrew Claster, Director of Marketing & Communication at Julia Computing to get a sense of what Julia is and where they...
Page 1 of 212»

Recent Posts

  • Award-Winning Data CRO Expands Executive Leadership to Support Company’s Next Stage of Growth
  • What is FDA’s Project Renewal? The Modernization of Decades Old Oncology Drug Labels
  • FDA Updates IND Expanded Access Guidance for Industry
  • What is Regulatory Information Management System (RIMS)?
  • Expanded Access to IND – Full Question and Answer in Draft Guidance

Tags

biostatistics Careers clinical research clinical study reports clinical trial disclosure clinical trials clinical trial transparency Compliance conference COVID-19 CRO data management data privacy data science decentralized clinical trials diversity and inclusion drug development eCOA & ePro EMA FDA Functional Service Provider (FSP) GXP auditing Health Analytics Collective innovation Lay summaries leadership medical writing MMS Academy NDA submission News Orphan Drug Designation Applications PDUFA VII pharmacovigilance PhUSE plain language summary Policy 0070 Praxis bioresearch quality and compliance quality control rare disease real world data regulatory affairs regulatory operations statistical programming transparency